Skip to main content

News & Events

News & Announcements

TECHNICAL.LY BALTIMORE: PARAGON PICKS UP MORE MD. MANUFACTURING SPACE IN $18M DEAL WITH NOVAVAX

Along with assuming control of the biotech facilities in Gaithersburg, more than 100 Novavax employees will join the Baltimore-based gene therapy unit.

Baltimore’s Paragon is adding more space for biotech manufacturing in Maryland.

Through a partnership with Paragon Gene Therapy parent Catalent Biologics, the gene therapy-focused unit is assuming two clinical development and manufacturing sites currently operated by Gaithersburg-based vaccine developer Novavax and acquiring manufacturing equipment for $18 million in cash, the companies announced on Thursday.

Read the full story at Technical.ly Baltimore.